Enzymes and Catalysis: How They Accelerate Biochemical Reactions

Competitive inhibition occurs when inhibitors compete with substrates for the active site, reversible by increasing substrate concentration. Non-competitive inhibition involves binding to allosteric sites, changing enzyme shape and reducing activity regardless of substrate concentration. The methanol poisoning example demonstrates competitive inhibition: ethanol competes with methanol for alcohol dehydrogenase's active site. However, because ethanol binds 10,000 times more strongly than methanol, the inhibition is practically irreversible in the body.

Non-competitive inhibition involves inhibitors binding to allosteric sites (regulatory sites distinct from the active site). This binding induces conformational changes that alter the active site's shape, preventing substrate binding regardless of substrate concentration. Unlike competitive inhibition, increasing substrate concentration cannot overcome this type of inhibition because the fundamental problem is structural distortion rather than occupancy competition.

Competitive inhibition occurs when inhibitors structurally resemble substrates and compete for binding at the enzyme's active site. While bound, inhibitors prevent substrate access without being processed by the enzyme. This inhibition is reversible and causes the apparent Km to increase while Vmax remains unchanged. Non-competitive (allosteric) inhibition involves binding at a separate allosteric site, inducing conformational changes that distort the active site. Unlike competitive inhibition, substrate and inhibitor don't compete for the same site. Both mechanisms reduce reaction rates but affect kinetic parameters differently, with competitive inhibition showing characteristic shifts in substrate requirement curves.

This comprehensive section covers three types of reversible enzyme inhibition. Competitive inhibition involves structurally similar inhibitors binding to the active site, blocking substrate access; this increases Km but leaves Vmax unchanged, as higher substrate concentrations can overcome inhibition. Non-competitive inhibition occurs when inhibitors bind to allosteric sites on either free enzyme or enzyme-substrate complexes, preventing product formation without affecting substrate binding; this keeps Km normal but decreases Vmax since not all enzyme-substrate complexes can form product. Both mechanisms follow Le Chatelier's principle, with competitive inhibition shifting equilibrium toward substrate binding through increased substrate concentration. Practical applications include statins (cholesterol-lowering HMG-CoA reductase inhibitors), ACE inhibitors (hypertension treatment), monoamine oxidase inhibitors (depression therapy), and oxamic acid (gluconeogenesis inhibition).

Non-competitive inhibition occurs when the inhibitor binds to a site other than the active site (allosteric site) on the enzyme molecule. Key characteristics include: (1) The inhibitor does not compete with the substrate for the active site; (2) The inhibitor can bind to either the free enzyme or the enzyme-substrate complex; (3) The inhibitor causes a conformational change in the enzyme that prevents substrate binding or catalysis; (4) Km remains unchanged because the substrate can still bind to the enzyme; (5) Vmax decreases because the enzyme-inhibitor complex cannot catalyze the reaction. Uncompetitive inhibition occurs when the inhibitor binds only to the enzyme-substrate complex, not to the free enzyme. Both Km and Vmax decrease because the inhibitor stabilizes the enzyme-substrate complex and prevents product formation. Suicide inhibition (mechanism-based inhibition) occurs when the inhibitor is converted by the enzyme into a more potent inhibitor. The enzyme itself catalyzes the conversion of the inhibitor into its active form, which then binds irreversibly to the enzyme.

Coenzymes, cofactors, and prosthetic groups are small nonprotein molecules or metal ions that directly participate in substrate binding or catalysis during enzyme action. Coenzymes are organic, nonprotein, low molecular weight (LMW), and dialysable substances that associate with enzymes to facilitate their function. Cofactors refer specifically to metal ions that are loosely bound to enzymes, enabling their catalytic activity. Prosthetic groups differ in that they form tight and stable associations with enzymes, remaining permanently attached during enzymatic reactions. These components are classified based on two criteria: the precursor molecule from which they are derived and the type of chemical group they transfer during reactions. This classification helps distinguish their roles in biochemical pathways and their structural relationships with enzymes. Their presence is essential for the proper functioning of many enzymes, as they often act as carriers of specific atoms or functional groups, such as electrons, methyl groups, or acyl groups, thereby expanding the catalytic versatility of enzymes beyond what amino acid residues alone can achieve.

Coenzymes, cofactors, and prosthetic groups are non-protein components that assist enzymes in their catalytic function. Coenzymes are non-protein organic low molecular weight molecules that are easily separable and are generally derived from vitamin B complex. Examples include: (1) Thiamine pyrophosphate - important in oxidative decarboxylation reactions; (2) Flavin adenine dinucleotide (FAD) - important in oxidation-reduction reactions; (3) NAD+ - important in oxidation-reduction reactions; (4) Coenzyme A - important in acyl group transfer; (5) Biotin - important in carboxylation reactions; (6) Tetrahydrofolate - important in one-carbon metabolism; (7) Coenzyme A - important in acyl group transfer. Cofactors are generally metal ions that attach to enzymes by weak and transient associations. Prosthetic groups are attached to apoenzymes by tight and stable forces.

Cofactors are non-protein molecules essential for enzyme function. They can be inorganic ions (metal ions) or organic molecules (coenzymes). Prosthetic groups are cofactors that bind tightly to enzymes and remain associated during the reaction. Coenzymes bind loosely and can be regenerated after participating in reactions. Examples of coenzymes include NAD+, FAD, and coenzyme A, which are derived from vitamins. Prosthetic groups include heme (in hemoglobin) and biotin (in carboxylases). Cofactors participate directly in the catalytic mechanism by stabilizing transition states, facilitating electron transfer, or carrying chemical groups between reactions.

Complex enzymes require cofactors (مرافق إنزيمية) to function. Cofactors can be metal ions (like Mg²⁺, Zn²⁺) or organic molecules (like vitamins). They bind to the enzyme and participate in the catalytic reaction. Cofactors are not consumed during the reaction and can be reused. Without cofactors, complex enzymes cannot catalyze their reactions.

Enzymes, which are proteins that lower activation energy to catalyze reactions, often require cofactors—non-protein molecules or ions—to function properly; these cofactors are subdivided into inorganic cofactors (such as magnesium ions that help manage electrons) and organic coenzymes (such as NAD, which facilitates hydride ion transfer in metabolic reactions).

Enzyme inhibition is categorized into three main types: competitive inhibition (where inhibitor competes with substrate for the active site, increasing Km but leaving Vmax unchanged), non-competitive inhibition (where inhibitor binds to a different site, decreasing Vmax without affecting Km), and uncompetitive inhibition (where inhibitor binds only to the enzyme-substrate complex, decreasing both Vmax and apparent Km); these mechanisms are applied in drug development, such as sulfa drugs that competitively inhibit bacterial folic acid synthesis and protease inhibitors for treating HIV and Alzheimer's disease.

Enzyme inhibition occurs through competitive, non-competitive, and irreversible mechanisms. Competitive inhibitors bind to the active site, competing with substrate binding; their effect can be overcome by increasing substrate concentration. Non-competitive inhibitors bind to allosteric sites, changing enzyme shape and reducing activity regardless of substrate concentration. Irreversible inhibitors form permanent bonds with the enzyme, permanently inactivating it. Zymogens are inactive enzyme precursors that require activation by removing peptide segments. Trypsinogen is activated in the small intestine by enterokinase, while pepsinogen is activated in the stomach by acid. Cofactors assist enzyme function and include metal ions and coenzymes (often vitamin-derived). Enzymes are classified by structure: monomeric (single polypeptide), oligomeric (multiple subunits), and complex (protein plus cofactor). Industrial enzyme production uses microorganisms for rapid growth, low cost, and genetic modification. Bioreactors provide controlled conditions for enzyme production. Industrial enzymes have diverse applications: amylase converts starch to glucose syrup; glucose isomerase produces fructose for high-fructose corn syrup; pectinase improves juice clarity; proteases reduce protein in baking and break down stains; rennet coagulates milk for cheese; lactase helps lactose-intolerant individuals digest dairy. Immobilized enzymes allow reuse and improved stability.

Enzymes require cofactors (inorganic ions) or coenzymes (organic molecules) for function. Inhibition occurs through competitive binding (inhibitor resembles substrate), non-competitive binding (inhibitor changes enzyme shape), or feedback inhibition (product inhibits earlier enzyme). These mechanisms are crucial for medicine: competitive inhibition treats poisonings, while inhibitors serve as drugs for pain, infections, and metabolic disorders. Understanding inhibition enables drug development targeting specific enzymes to control biological processes.

Enzyme inhibitors are substances that decrease or stop enzyme activity, classified into reversible (competitive, non-competitive, uncompetitive) and irreversible types; they have significant therapeutic importance in medicine, such as sulphonamides for bacterial infections through competitive inhibition, MAO inhibitors for depression, and allopurinol for gout, while enzymes themselves are crucial for drug manufacturing, disease diagnosis through plasma enzyme levels, and industrial processes.

This segment examines enzyme inhibition and its practical applications across various fields. The speaker discusses competitive and non-competitive inhibition, explaining how inhibitors bind to enzymes and affect their catalytic activity. The content explores the importance of enzyme inhibition in drug development and therapeutic applications. Additionally, the section covers industrial applications of enzymes in food processing, detergents, and biofuel production, demonstrating the practical significance of enzyme science in modern industry and medicine.